Summit Therapeutics Inc. announced that it has determined its first two indications in non-small cell lung cancer (NSCLC) in which to pursue Phase III clinical trials for its innovative, potential first-in-class bispecific antibody, ivonescimab. Summit has held multiple meetings with the US Food and Drug Administration (FDA) during the first quarter of 2023 regarding its planned Phase III clinical program and incorporated this feedback accordingly. The company plan to initiate clinical studies in the following indications: Ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)- mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) (HARMONi) (HARMONi).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.38 USD | -21.76% | -23.87% | +29.50% |
24/05 | Sector Update: Health Care Stocks Decline Late Friday Afternoon | MT |
24/05 | Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+29.50% | 3.03B | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- SMMT Stock
- News Summit Therapeutics Inc.
- Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab